Erin Schendel
Physician Assistant · San Antonio, TXNPI 1679805253
Payments from drug & device makers
Across 211 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$702
- Lilly USA, LLC$658
- Novo Nordisk$550
- Amgen$455
- Johnson & Johnson$395
- Novartis$320
- plus $1K from 20 others
What the payments were for
- Food & beverage$4,105100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 35 | $702 |
| Lilly USA, LLC | 38 | $658 |
| Novo Nordisk | 29 | $550 |
| Amgen(2 entities) | 24 | $455 |
| Johnson & Johnson | 18 | $395 |
| Novartis | 16 | $320 |
| Boehringer Ingelheim | 6 | $152 |
| AstraZeneca(2 entities) | 8 | $137 |
| Fresenius Kabi USA, LLC | 4 | $123 |
| Merck | 5 | $94 |
| Aurinia Pharma U.S., Inc. | 3 | $88 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $77 |
| GSK | 3 | $49 |
| Idorsia Pharmaceuticals US Inc | 3 | $48 |
| Exact Sciences | 2 | $36 |
| Bayer | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Astellas Pharma US Inc | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Eisai Inc. | 1 | $18 |
| Vistapharm, Inc. | 1 | $15 |
| Pfizer | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Genentech USA, Inc. | 1 | $11 |
How this compares
$4,105 in reported general payments places this provider in the 85th percentile of 8,308 physician assistant providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 21 | $18,711 |
| RybelsusSemaglutide | 17 | $15,287 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $6,635 |
| Levothyroxine Sodium | 63 | $776 |
| Fluticasone Propionate | 25 | $684 |
| Valsartan | 17 | $641 |
| Rosuvastatin Calcium | 62 | $533 |
| Duloxetine Hcl | 23 | $506 |
| Metoprolol Succinate | 19 | $416 |
| Tamsulosin Hcl | 44 | $410 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 13 | $379 |
| Pantoprazole Sodium | 19 | $274 |
| Lisinopril | 30 | $272 |
| Atorvastatin Calcium | 41 | $271 |
| Losartan Potassium | 23 | $270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $550 | $33,99838 claims |
| Boehringer IngelheimSynjardy Xr | $152 | $6,63512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in San Antonio
- Anthony DerenciusSan Antonio$507K
- Andrew PrattSan Antonio$87K
- Sarah MerrittSan Antonio$55K
- Monica ChapmanSan Antonio$38K
- Lisa GarrisonSan Antonio$35K
- Cynthia TrickettDallas$1.3M
- Kristine KuceraMelissa$797K
- Selina SantosAustin$543K
- Matthew BrunoMcKinney$538K
- Brooke HodnickSouthlake$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.